What is LOPJLB’s current signal on HCWB?

LOPJLB’s latest quantitative signal on HCW Biologics Inc. (HCWB) is SELL in a CRISIS regime. Signals are updated daily.

What market regime is HCWB in?

HCW Biologics Inc. (HCWB) is currently classified in the CRISIS HMM market regime on LOPJLB.

What does HCW Biologics Inc. (HCWB) do?

HCW Biologics Inc. operates as a preclinical-stage biopharmaceutical firm, primarily engaged in the discovery and advancement of novel immunotherapies. Its research and development efforts are focused on addressing chronic, low-grade inflammation and a spectrum of age-related diseases. The company's leading therapeutic candidates include HCW9218, an injectable immunotherapeutic designed for pat…

HCW Biologics Inc. (HCWB)

COMPARE

Healthcare · Biotechnology · NASDAQ · US

$1.26-14.86%Close

SELLCRISIS · day 28

Company news

defenseworld.net · 3d ago

HCW Biologics Inc. (NASDAQ:HCWB) Shares Shorted: Short Interest Up 557.1% in September

globenewswire.com · 5d ago

HCW Biologics Maintains Momentum Toward Completion of IND Application for Clinical Study to Evaluate Lead T-Cell Engager in Solid Tumors

globenewswire.com · 20d ago

HCW Biologics Announces Pricing of $1.5 Million Private Placement

globenewswire.com · 36d ago

HCW Biologics Entered an Exclusive Distribution Agreement with Akron Biotech to Commercialize HCW11-006 as Reagent Used to Support Production of Highly Functional Human CAR-T Cells

globenewswire.com · 42d ago

HCW Biologics Strengthens U.S. Patent Estate for Its Lead Clinical-Stage Immunotherapeutic HCW9302 as Alopecia Areata Treatment

globenewswire.com · 50d ago

HCW Biologics' TGF-β Trap and IL-15 Fusion is a Novel Moiety to Enhance Immunotherapeutic Activity against Diseased Cells

globenewswire.com · 61d ago

HCW Biologics Reports Second Quarter 2026 Business and Clinical Development Highlights and Financial Results

globenewswire.com · 77d ago

HCW Biologics Inc. Announces Pricing of $1.6 Million Private Placement Offering

globenewswire.com · 83d ago

HCW Biologics Reaches Milestones for Its Proprietary Tetravalent Second-Generation T-Cell Engager Program On Track To Initiate Clinical Trials in First Half 2027

Market news & ticker search · RSS for HCWB

FAQ

What is LOPJLB’s current signal on HCWB?: LOPJLB’s latest quantitative signal on HCW Biologics Inc. (HCWB) is SELL in a CRISIS regime. Signals are updated daily.
What market regime is HCWB in?: HCW Biologics Inc. (HCWB) is currently classified in the CRISIS HMM market regime on LOPJLB.
What does HCW Biologics Inc. (HCWB) do?: HCW Biologics Inc. operates as a preclinical-stage biopharmaceutical firm, primarily engaged in the discovery and advancement of novel immunotherapies. Its research and development efforts are focused on addressing chronic, low-grade inflammation and a spectrum of age-related diseases. The company's leading therapeutic candidates include HCW9218, an injectable immunotherapeutic designed for pat…

HCW Biologics Inc. (HCWB)

Key stats

Prediction markets

Company news

FAQ